CTD Dossier Templates for the US and EU Regulatory Authorities
Accelerate Your Path to Market with Zenovel’s expert regulatory solutions and dossier templates USA-EU, from IND to MAA
Accelerate Your Path to Market with Zenovel’s expert regulatory solutions and dossier templates USA-EU, from IND to MAA
Most regulatory applications must be submitted in ICH-harmonized CTD format, as per EU and US Health Authority regulations. Efficient management of submissions and lifecycles is achieved through a thorough submission methodology and standardized CTD dossier templates, all within reasonable time and financial constraints.
We offers customized CTD dossier templates for various regulatory applications, including INDs, IMPDs, MAAs, BLAs, NDAs, and ANDAs for pharmaceutical and biological goods, making them easier to understand and utilize.
Our IND templates simplify the authoring and submission of Phase I, II, and III clinical trial applications to the US FDA. These templates provide detailed information on regulatory requirements for biological and pharmaceutical goods, allowing applicants to comply with FDA expectations. The metadata also provides in-depth information on potential clinical-hold problems related to Clinical Management Control (CMC) requirements and advice on handling CMC-related clinical-hold problems.
We have developed CTD templates for US and EU biologics marketing authorization dossier submissions. These templates are encrypted with specific metadata for each agency and application, providing guidance on regulatory requirements and potential issues like application-hold and refuse-to-file. The metadata also outlines standard specifications for biological products and production processes. The applicant can adhere to unique metadata for each application type and agency, and the same CTD data package can be updated or modified for the next country-submission.
We has personalised templates simplify the creation and submission of an IMPD for clinical programmes to EU HAs and member states. These templates must satisfy pharmaceutical and biological product regulations, allowing applicants to adhere to metadata based on product type to meet HA needs and expectations.
Pharmaceutical product innovators can file for innovations in generic pharmaceuticals under the FDC Act by altering formulation, components, administration method, dosage schedule, and API using customised NDA 505(b) 2 templates. These templates provide regulatory references for most RTR concerns for all types of pharmaceutical products, including tablets, capsules, solutions, suspensions, injectable, and topical.
Insufficient understanding of GDUFA II, RTR prerequisites, and ANDA readiness can lead to ANDA rejections, costing company’s time and money. To avoid this, company should submit an ANDA using the correct data presentation strategy, including in-depth details and regulatory references for various generic medicine dosage forms.
MAA CTD templates have been prepared for EU MAAs relating to pharmaceutical items, containing encrypted metadata outlining regulatory requirements for generic pharmaceutical goods in various formulation forms such as tablets, capsules, solutions, suspensions, and injectables, to be submitted via relevant processes.
Ensure your submission meets highest standards by our deep understanding of the regulatory process- US and EU authorities.
Our pre-formatted templates and checklists are easy to edit, allowing you to customize documents.
For product registration, each template is encrypted with specific metadata prepared by regulatory experts.
India is a significant player in the global pharmaceuticals sector, characterized by a diverse population and cost-effective infrastructure. However, its potential in clinical research is hindered by complex regulatory challenges that delay innovations and deter investment, affecting the timely market introduction of life-saving drugs. This blog discusses the major obstacles
The FDA issued 466 Form 483s to drug organizations in FY 2022, more than double the previous year, highlighting significant quality failures in the pharmaceutical sector. For startups and scale-ups seeking market approval, the excitement of innovation often conflicts with the strict requirements of current good manufacturing practices (cGMP). Although
Introduction Liposomal Amphotericin-B is a critical antifungal medication that requires careful attention during Bioequivalence (BE) studies. These studies aim to demonstrate the similarity of a generic liposomal Amphotericin B formulation to the reference drug in terms of pharmacokinetics. Zenovel, with its extensive experience in monitoring Amphotericin B studies, can play
In the pharmaceutical and biotechnology industries, obtaining regulatory approval is essential prior to introducing new drugs or biologics to the market. A pivotal aspect of this approval process is the FDA Pre-Approval Inspection (PAI), which involves a comprehensive assessment of manufacturing facilities, processes, and data integrity to ensure adherence to
Risk Based Monitoring (RBM) is a more efficient alternative to traditional clinical trials, focusing on high-risk areas through data-driven insights. It ensures patient safety, data integrity, and regulatory compliance while reducing costs and timelines. However, the success of RBM depends on the competency of monitors, who identify risks, analyze data,
Welcome to the Zenovel Blog! We are a leading provider of drug regulatory consulting and education, focusing on advancing pharmaceutical innovation while ensuring safety and compliance. This blog delves into the essentials of Drug Regulatory Affairs (DRA), covering its scope, career opportunities, and intricate processes involved in bringing new drugs
We provide affordable, innovative, and high-quality solutions to pharma industry with ethics driven research and increasing accessibility to high quality medicine worldwide
Copyright © 2024 Zenovel. All rights reserved.